MyndTec Inc. — Investor Relations & Filings

MyndTec Inc. develops and commercializes innovative neurotechnology products focused on improving function and independence for individuals with neurological disorders, including paralysis due to stroke or spinal cord injury (SCI). The company operates across neuromodulation and regenerative medicine. Its primary commercial product is MyndMove™, a non-invasive functional electrical stimulation therapy authorized in the U.S. and Canada. MyndMove promotes neuroplasticity to help patients regain motor control and sensation. Expanding its portfolio, MyndTec is developing MyndLink™, an AI-powered software platform that provides personalized insights to optimize existing neurological treatments, such as Spinal Cord Stimulators (SCS), aiming to reduce unnecessary procedures and healthcare costs. The company is also advancing preclinical research in cell regeneration technology, utilizing neural stem cells guided by electrical stimulation for brain tissue repair in conditions like Parkinson’s and Alzheimer’s.